| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Wendye Robbins last filed a Form 4 in March 2025, as Director at RAPT. Wendye Robbins's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Wendye Robbins a middling insider score of 59/100, based on 11 past trades. Over a 12-month horizon, 27.3% of those trades were profitable, with an average 12-month return of -11.8%.
At the last filing, the largest reported position was 6,500 shares of RAPT. Net of sales, the RAPT filings show accumulation of 26,505 shares.
Wendye Robbins has 29 Form 4 filings on record from October 2019 to March 2025, all as Director at RAPT Therapeutics (RAPT), 2019–2025.
The 63 reported transactions were 49 open-market purchases, 12 option or other derivative awards and 2 gifts.
Counted by filing, the open-market trades come to 16 purchases worth about $533K and no sales.
The largest open-market purchase was 5,000 shares of RAPT at an average $19.52 on March 14, 2023, about $98K. Twelve months later RAPT was down 56%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2023 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 5,000 | $19.52 | $97,612.00 | +333.3% | +4.5% | -56.4% | |
| May 10, 2022 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 7,000 | $11.04 | $77,282.00 | -233.3% | +95.7% | +77.4% | |
| Oct 18, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 500 | $30.70 | $15,350.00 | +5.7% | -21.5% | -27.3% | |
| Oct 13, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 400 | $29.69 | $11,876.00 | +4.8% | +9.3% | -26.3% | |
| Aug 24, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 2,000 | $31.28 | $62,564.95 | New | +3.4% | -8.0% | |
| Aug 20, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 600 | $29.53 | $17,716.50 | +7.7% | +18.3% | -10.9% | |
| Jul 7, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 1,000 | $30.18 | $30,180.00 | +14.7% | -2.9% | -34.9% | |
| Jun 16, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 705 | $31.54 | $22,237.04 | -176.3% | +16.2% | -54.3% | |
| Apr 13, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 700 | $19.46 | $13,620.00 | +13.0% | +72.0% | +13.9% | |
| Apr 9, 2021 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 1,400 | $21.07 | $29,504.87 | -1,400% | +60.2% | +12.0% |